Literature DB >> 3080477

Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

G B Pier, S E Bennett.   

Abstract

We analyzed high molecular weight polysaccharide (PS) from the Fisher immunotype 2 (IT-2) strain of Pseudomonas aeruginosa for molecular composition and structure, then determined its immunogenicity in healthy adults. The PS was composed of 2-acetamido-2,6-dideoxygalactose (N-acetyl fucosamine) and glucose in a molar ratio of 2:1. Structural analysis by carbon-13 and proton nuclear magnetic resonance confirmed that the high molecular weight PS was structurally identical to that of the O-specific side chain of the lipopolysaccharide. PS differed from this material in molecular size. Immunization of 19 adult volunteers with doses of 50-100 micrograms of PS resulted in significant rises (P less than 0.04-P less than 0.0001) in binding antibody levels and killing antibody titers 2 and 4 wk postimmunization. The only reaction to the vaccine was localized tenderness at the immunization site. Analysis of the immunoglobulin isotype response to the vaccine showed a rise in specific serum IgG and IgA antibodies. Heterologous responses to other P. aeruginosa PS antigens were not seen. The antibody levels attained by vaccination were comparable with those in acute-phase serum samples of patients who survived sepsis with IT-2 P. aeruginosa and were significantly higher (P less than 0.03) than specific antibody levels in bacteremic patients who died. These results confirm that PS is a high molecular weight, immunogenic form of the P. aeruginosa IT-2 serotype antigen, eliciting levels of type-specific antibody comparable with those seen among patients surviving an episode of P. aeruginosa sepsis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080477      PMCID: PMC423370          DOI: 10.1172/JCI112328

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis.

Authors:  J E Pennington
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

2.  Type-specific immunity in pseudomonas diseases.

Authors:  J G Crowder; M W Fisher; A White
Journal:  J Lab Clin Med       Date:  1972-01

3.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

4.  Controlled trials of a polyvalent pseudomonas vaccine in burns.

Authors:  R J Jones; E A Roe; J L Gupta
Journal:  Lancet       Date:  1979-11-10       Impact factor: 79.321

5.  Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.

Authors:  M Pollack; G B Pier; R K Prescott
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

6.  Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.

Authors:  G B Pier; M Pollack; M Cohen
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

7.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

8.  Antibody response to capsular polysaccharides of groups A and C neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease.

Authors:  H Käyhty; H Jousimies-Somer; H Peltola; P H Mäketä
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

9.  Agar-Gel Precipitating Antibody in Pseudomonas aeruginosa Infections.

Authors:  L S Young; B H Yu; D Armstrong
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

10.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors:  M Pollack
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

View more
  9 in total

1.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

2.  Increased elastase secretion by peripheral blood monocytes in cystic fibrosis patients.

Authors:  M M Jones; D K Seilheimer; G B Pier; R D Rossen
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

3.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

4.  In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

Authors:  G B Pier; D Thomas; G Small; A Siadak; H Zweerink
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

5.  Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.

Authors:  G B Pier; M Pollack
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

6.  Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

Authors:  J F Pittet; M A Matthay; G Pier; M Grady; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

7.  Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Authors:  G B Pier; N L Koles; G Meluleni; K Hatano; M Pollack
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

8.  Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.

Authors:  K Hatano; G B Pier
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

9.  Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Authors:  K Hatano; S Boisot; D DesJardins; D C Wright; J Brisker; G B Pier
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.